Back to Search Start Over

Atherogenic LOX-1 signaling is controlled by SPPL2-mediated intramembrane proteolysis

Authors :
Mentrup, Torben
Theodorou, Kosta
Cabrera-Cabrera, Florencia
Helbig, Andreas O.
Happ, Kathrin
Gijbels, Marion
Gradtke, Ann-Christine
Rabe, Björn
Fukumori, Akio
Steiner, Harald
Tholey, Andreas
Fluhrer, Regina
Donners, Marjo
Schröder, Bernd
Source :
The Journal of Experimental Medicine; April 2019, Vol. 216 Issue: 4 p807-830, 24p
Publication Year :
2019

Abstract

The lectin-like oxidized LDL receptor 1 (LOX-1) is a key player in the development of atherosclerosis. LOX-1 promotes endothelial activation and dysfunction by mediating uptake of oxidized LDL and inducing pro-atherogenic signaling. However, little is known about modulators of LOX-1–mediated responses. Here, we show that the function of LOX-1 is controlled proteolytically. Ectodomain shedding by the metalloprotease ADAM10 and lysosomal degradation generate membrane-bound N-terminal fragments (NTFs), which we identified as novel substrates of the intramembrane proteases signal peptide peptidase–like 2a and b (SPPL2a/b). SPPL2a/b control cellular LOX-1 NTF levels which, following self-association via their transmembrane domain, can activate MAP kinases in a ligand-independent manner. This leads to an up-regulation of several pro-atherogenic and pro-fibrotic targets including ICAM-1 and the connective tissue growth factor CTGF. Consequently, SPPL2a/b-deficient mice, which accumulate LOX-1 NTFs, develop larger and more advanced atherosclerotic plaques than controls. This identifies intramembrane proteolysis by SPPL2a/b as a novel atheroprotective mechanism via negative regulation of LOX-1 signaling.

Details

Language :
English
ISSN :
00221007 and 15409538
Volume :
216
Issue :
4
Database :
Supplemental Index
Journal :
The Journal of Experimental Medicine
Publication Type :
Periodical
Accession number :
ejs49691863
Full Text :
https://doi.org/10.1084/jem.20171438